CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.
In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.
According to the Wall Street Journal, Becton Dickinson is investigating reports from nursing homes regarding false positive results from its rapid COVID-19 test.
In Genome Biology this week: improved reference genome for the Asian tiger mosquito Aedes albopictus, links between Ebola variants and outcomes, and more.
According to the Los Angeles Times, National Institutes of Health officials are concerned about the possible side effect reported by a COVID-19 vaccine trial.
Politico reports that political appointees are interfering with what appears in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Reports.
CNBC reports NIH Director Francis Collins told a congressional committee that assessing the safety and efficacy of COVID-19 vaccine is the agency's "top priority."
CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.
In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.
